Asset profile
BCMA CAR-NK (Hrain)
Cell therapy
Evidence outlook · results not reported
NCT03940833 · Multiple Myeloma
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT03940833: This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 20 participants, and it measured only safety. Results have not been posted yet.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
92 competitors in this universe: 32 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 61 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BCMA CAR-NK (Hrain): this drug | Phase 1/2 | Cell therapy | BCMA | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Anitocabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | ||
| Equecabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | ||
| HRC0202 | Phase 2 | Cell therapy | BCMA | ||
| PHE885 | Phase 2 | Cell therapy | BCMA | ||
| AZD4045 | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA CAR-NK (Shenzhen Pregene Biopharma) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-CART (Bioray Laboratories) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech) | Phase 1/2 | Cell therapy | BCMA | ||
| GSK2857914 | Phase 1/2 | Monoclonal antibody | BCMA | ||
| Pamlectabart Tismanitin | Phase 1/2 | Adc (anti-bcma Antibody-targeted Amanitin Conjugate) | BCMA | ||
| SENL103 | Phase 1/2 | Cell therapy | BCMA | ||
| Trovocabtagene Autoleucel (C-CAR088) | Phase 1/2 | Cell therapy | BCMA |
…and 77 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
26 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (2)
June 2028 (2)
What to watch
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.